特泊替尼片 | China Drugs ListTepotinib tablets | China Drugs List

本页为公开参考信息,不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。

其他

商品名
Tepmetko
企业
Merck Europe B.V. (欧盟上市许可持有人)Merck Europe B.V. (EU authorization holder)
药品类型
化学药Chemical medicine
治疗领域
肿瘤科Oncology
公开来源记录的适应症
欧盟部分适应症:用于携带MET外显子14跳跃改变、在免疫治疗和/或铂类化疗后需要进一步治疗的成人晚期非小细胞肺癌。须确认生物标记。本摘要不确立中国批准的适应症范围。Selected EU indications: For adults with advanced non-small cell lung cancer carrying MET exon 14 skipping alterations who need further treatment after immunotherapy and/or platinum-based chemotherapy. Biomarker confirmation is required. This summary does not establish the approved indications in China.
适应症来源与口径
网页 查阅于 2026-11-02. 部分境外适应症;不确立中国批准范围。Web page accessed 2026-11-02. Selected overseas indications; does not establish the Chinese approved scope.
说明书信息局限
已链接监管机构产品资料/批准证据;本次核查尚未核实完整的现行处方资料文件。Regulatory product information / approval evidence is linked; a complete current prescribing-information document has not been verified in this review.
中国可获得性状态
本次英文来源核查未独立核实中国批准、现行中国适应症及持续在售情况。Chinese approval, current Chinese indications and continuous market availability were not independently verified in this English-source review.
海外状态
请参阅所链接的境外监管机构或厂商证据。批准及适应症因司法辖区而异;尚未确认当前供应情况。See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
医保分类
尚未核实Not yet verified
医保版本
中国国家医保信息待核实Chinese national insurance review pending
医保核查说明
本次新增记录尚未确定报销资格;缺少信息不代表未被纳入。No reimbursement determination was made for this addition; missing information is not proof of exclusion.

来源

证据核查日期:

打开交互详情、公开价格与讨论